These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 24097843

  • 1. Raltegravir pharmacokinetics in HIV/HCV-coinfected patients with advanced liver cirrhosis (Child-Pugh C).
    Hernández-Novoa B, Moreno A, Pérez-Elías MJ, Quereda C, Dronda F, Casado JL, Madrid-Elena N, Aguilar M, Fumero E, Moltó J, Moreno S.
    J Antimicrob Chemother; 2014 Feb; 69(2):471-5. PubMed ID: 24097843
    [Abstract] [Full Text] [Related]

  • 2. Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients.
    Calza L, Danese I, Colangeli V, Manfredi R, Magistrelli E, Verucchi G, Conti M, Motta R, Viale P.
    Infect Dis (Lond); 2015 Sep; 47(9):625-36. PubMed ID: 25875396
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial.
    Gallien S, Braun J, Delaugerre C, Charreau I, Reynes J, Jeanblanc F, Verdon R, de Truchis P, May T, Madelaine-Chambrin I, Aboulker JP, Molina JM, EASIER ANRS 138 Study Group.
    J Antimicrob Chemother; 2011 Sep; 66(9):2099-106. PubMed ID: 21712241
    [Abstract] [Full Text] [Related]

  • 6. Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus coinfection.
    Rockstroh J, Teppler H, Zhao J, Sklar P, Harvey C, Strohmaier K, Leavitt R, Nguyen BY.
    HIV Med; 2012 Feb; 13(2):127-31. PubMed ID: 21599819
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetic interactions between telaprevir and antiretroviral drugs in HIV/HCV-coinfected patients with advanced liver fibrosis and prior HCV non-responders.
    Milazzo L, Cattaneo D, Calvi E, Gervasoni C, Mazzali C, Ronzi P, Peri AM, Ridolfo AL, D'Avolio A, Antinori S.
    Int J Antimicrob Agents; 2015 May; 45(5):545-9. PubMed ID: 25769784
    [Abstract] [Full Text] [Related]

  • 8. Raltegravir: the first HIV integrase inhibitor.
    Cocohoba J, Dong BJ.
    Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Darunavir and ritonavir total and unbound plasmatic concentrations in HIV-HCV-coinfected patients with hepatic cirrhosis compared to those in HIV-monoinfected patients.
    Curran A, Martí R, López RM, Pérez M, Crespo M, Melià MJ, Navarro J, Burgos J, Falcó V, Ocaña I, Ribera E.
    Antimicrob Agents Chemother; 2015 Nov; 59(11):6782-90. PubMed ID: 26282411
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics of the combination raltegravir/atazanavir in HIV-1-infected patients.
    Jansen A, Colbers EP, van der Ven AJ, Richter C, Rockstroh JK, Wasmuth JC, van Luin M, Burger DM.
    HIV Med; 2013 Aug; 14(7):449-52. PubMed ID: 23506243
    [Abstract] [Full Text] [Related]

  • 17. A reduced grade of liver fibro-steatosis after raltegravir, maraviroc and fosamprenavir in an HIV/HCV co-infected patient with chronic hepatitis, cardiomyopathy, intolerance to nelfinavir and a marked increase of serum creatine phosphokinase levels probably related to integrase inhibitor use.
    Degli Antoni A, Weimer LE, Manfredi R, Fragola V, Ferrari C.
    West Indian Med J; 2012 Dec; 61(9):932-6. PubMed ID: 24020238
    [Abstract] [Full Text] [Related]

  • 18. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N, Abdelsayed S, Veve M, Miller CD.
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [Abstract] [Full Text] [Related]

  • 19. Hepatic safety and tolerability of raltegravir among HIV patients coinfected with hepatitis B and/or C.
    Hurt CB, Napravnik S, Moore RD, Eron JJ.
    Antivir Ther; 2014 Mar; 19(4):415-22. PubMed ID: 24458137
    [Abstract] [Full Text] [Related]

  • 20. Raltegravir-based therapy in a cohort of HIV/HCV co-infected individuals.
    Taramasso L, Madeddu G, Ricci E, De Socio GV, Menzaghi B, Orofino G, Passerini S, Franzetti M, Maggi P, Dentone C, Martinelli C, Celesia BM, Penco G, Libertone R, Quirino T, Bonfanti P, Di Biagio A, CISAI Study Group.
    Biomed Pharmacother; 2015 Feb; 69():233-6. PubMed ID: 25661363
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.